A survey-based report on process intensification highlighted four common misconceptions that may be slowing manufacturing improvements across life sciences. The piece argues that teams should separate concerns that “intensification invites regulatory scrutiny” from evidence that regulators already support manufacturing innovation, including FDA guidance connected to approaches such as real-time release. The report notes that four out of five leaders at organizations that had not deployed intensification strategies cited regulatory concerns as a top barrier. It counters that earlier regulatory and quality guidance can increase confidence in moving forward with improvements. The survey was conducted with Thermo Fisher Scientific and BioPharma Dive, and the messaging centers on enabling measurable gains in throughput and efficiency without triggering avoidable execution risk.